EcoDrugPlus

Endothelin Receptor Type B

Ensembl ID : ENSFHEG00000021800
Gene Symbol: EDNRB
3 Cross references
200 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSFHEG00000019096
Gene Symbol: EDNRB
3 Cross references
178 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSFHEG00000000934
Gene Symbol: EZH2
3 Cross references
240 Possible Orthologues:

Ephrin Type-B Receptor 4-Like

Ensembl ID : ENSFHEG00000009005
Gene Symbol: LOC105923226
2 Cross references
166 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSFHEG00000008277
Gene Symbol: EGFRA
1 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSFHEG00000013426
Gene Symbol: EPHX2
2 Cross references
204 Possible Orthologues:

Equilibrative Nucleoside Transporter 1

Ensembl ID : ENSFHEG00000020143
Gene Symbol: LOC105927950
3 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSFHEG00000009288
Gene Symbol: ERBB2
1 Cross references
199 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSFHEG00000007977
Gene Symbol: ERBB3
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSFHEG00000008374
Gene Symbol: ERBB4
3 Cross references
243 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSFHEG00000011982
Gene Symbol: ERBB4
3 Cross references
222 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSFHEG00000000933
Gene Symbol: ESR1
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).